Back to Clinical Trials
Phase 2Recruiting

Neurovascular Transduction During Exercise in Chronic Kidney Disease

Sponsored by Emory University

About this study

The purpose of this study is to find out why patients with chronic kidney disease (CKD) have poor exercise capacity and to explore what causes an increase in blood pressure during exercise (i.e. increased adrenaline levels, or decreased ability of blood vessels to dilate). This study will also test whether or not regular exercise on a bicycle and/or treatment with 6R-BH4 (Kuvan) pills, or histidine and beta-alanine supplementation improves these measures during exercise. 6R-BH4 is currently FDA-approved for use in patients with certain forms of a disease called phenylketonuria, but it is not currently FDA approved for blood pressure or exercise capacity in people with CKD.

The major problem addressed in this study is to understand mechanisms underlying poor exercise capacity in patients with chronic kidney disease (CKD). Prior research has found that CKD patients have an exaggerated increase in blood pressure during certain forms of exercise that could contribute to exercise dysfunction as well as cardiovascular disease. This study will test the mechanisms underlying this exaggerated blood pressure response, as well as the potential benefits of simple measures such as exercise training on a stationary bicycle, and treatment with 6R-BH4, a drug that is currently FDA-approved for the treatment of phenylketonuria, but has been shown to have beneficial effects on vascular health in patients with kidney disease. This study will also examine the effects of exercis…

Where this study is enrolling (3)

Who can participate

Inclusion criteria

  • ✓for Chronic Kidney Disease Patients:
  • ✓Stage III or IV Chronic Kidney Disease, defined as reduction in estimated glomerular filtration rate (eGFR) to 15-59 cc/minute as calculated by the modified Modification of Diet in Renal Disease (MDRD) Study equation or the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
  • ✓Stable renal function, with no greater than a 30% reduction in eGFR over the prior 3 months
  • ✓Does not exercise regularly (defined as exercising less than 20 minutes twice per week)
  • ✓Willing and able to cooperate with the study protocol
  • ✓Inclusion Criteria for Control Study Participants:
  • ✓Does not exercise regularly (defined as exercising less than 20 minutes twice per week)
  • ✓Willing and able to cooperate with the study protocol

Exclusion criteria

  • ✕severe CKD (eGFR\<15 cc/minute)
  • ✕ongoing drug or alcohol abuse
  • ✕diabetic neuropathy
  • ✕any serious systemic disease that might influence survival
  • ✕severe anemia with hgb level \<9 g/dL
  • ✕clinical evidence of congestive heart failure or ejection fraction below 35%
  • ✕symptomatic heart disease determined by prior electrocardiogram, stress test, and/or history
  • ✕treatment with central alpha agonists (clonidine)
  • ✕uncontrolled hypertension with BP greater than 170/100 mm Hg
  • ✕low blood pressure with BP less than 100/50
  • ✕pregnancy or plans to become pregnant
  • ✕current treatment with monoamine oxidase (MAO) inhibitors
  • ✕inability to exercise on a stationary bicycle

Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.